{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-024154","form_type":"8-K","ticker":"ITRMF","cik":"0001659323","company_name":"Iterum Therapeutics plc","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.607758+00:00","generated_at":"2026-06-21T23:07:06.942385+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Iterum Q3 net loss $29.1M; starts uUTI trial; cash into 2024","bullets":["Net loss $29.1M vs income $3.7M YoY; non-GAAP net loss $5.3M.","Cash, equivalents & short-term investments $64.3M; runway into 2024.","R&D expense $4.4M (up from $1.8M) due to REASSURE trial startup.","Enrollment in Phase 3 REASSURE trial for uUTI began Oct 2022; completion expected H1 2024.","New US patent (No. 11,478,428) for oral sulopenem bilayer tablet extends protection to 2039."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-024154","json":"https://secwatch.observer/filing/0000950170-22-024154.json","markdown":"https://secwatch.observer/filing/0000950170-22-024154.md","text":"https://secwatch.observer/filing/0000950170-22-024154.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659323/000095017022024154/0000950170-22-024154-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659323/000095017022024154/itrm-20221110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T23:07:06.942385+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6de06992ada7ad67687bd3c94b4519f3b024e2cc","claim":"Iterum Therapeutics plc reported financial results for the third quarter ended September 30, 2022.","evidence_excerpt":"Iterum Therapeutics plc (Nasdaq: ITRM) (“Iterum”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the third quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1659323/000095017022024154/0000950170-22-024154-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}